No profile data available.
MBX Biosciences, Inc. (MBX) is a healthcare company in the additional hormone and metabolic drugs industry, based in Carmel, United States, with about 63 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$86.97 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $0. Its market capitalization was $2.56 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism.
MBX Biosciences reported $0 in revenue for fiscal year 2025. In Q1 2026 revenue was $0.
$2.56 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Corcept Therapeutics Incorporated (CORT), BridgeBio Pharma, Inc. (BBIO), Amylyx Pharmaceuticals, Inc. (AMLX), Xeris Biopharma Holdings, Inc. (XERS).